Trial · NCT01247571

Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer

NCT01247571, Phase 2, Completed, National Cancer Institute (NCI); results first posted 2017-07-27

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer. Trials, record NCT01247571. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01247571

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
NCT number: NCT01247571
Status: Completed
Phases: Phase 2
Enrollment: 22 participants, actual
Lead sponsor: National Cancer Institute (NCI)
Conditions: Recurrent Uterine Corpus Sarcoma, Uterine Carcinosarcoma
Interventions: Pazopanib Hydrochloride
First posted: 2010-11-24
Last updated: 2019-08-08
Results first posted: 2017-07-27

Source ClinicalTrials.gov

Registered outcomes5

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Objective Tumor Response (Complete or Partial)	CT scan or MRI if used to follow lesion(s) for measurable disease every other cycle for the first 6 mnths; then every 3 mnths thereafter until dx progression is confirmed; also repeat any other time clinically indicated, assessed up to 6 months.	Complete and Partial Tumor Response by RECIST 1.0. Per Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR
Primary	Percentage of Participants With Progression-free Survival (PFS) at 6 Months	6 months	Progression-free survival is the period from study entry until disease progression, death or date of last contact. Progression is defined using Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.0), as a 20 % increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
Primary	Number of Patients With Grade 3 or Higher Adverse Events	Every cycle while on treatment	Grade 3 or higher adverse events were graded by CTCAE v4.
Secondary	Progression-free Survival	From start of treatment to time of progression or death, assessed up to 5 years	Progression-free survival is the period from study entry until disease progression, death or date of last contact
Secondary	Overall Survival	Time from start of treatment to time of death or the date of last contact, assessed up to 5 years	The observed length of life from entry into the study to death or the date of last contact.

Source ClinicalTrials.gov

Outcomes5

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Objective Tumor Response (Complete or Partial)	CT scan or MRI if used to follow lesion(s) for measurable disease every other cycle for the first 6 mnths; then every 3 mnths thereafter until dx progression is confirmed; also repeat any other time clinically indicated, assessed up to 6 months.	Eligible and Treated Patients	percentage of participants	NUMBER
PRIMARY	Percentage of Participants With Progression-free Survival (PFS) at 6 Months	6 months	Eligible and treated patients	percentage of participants	NUMBER
PRIMARY	Number of Patients With Grade 3 or Higher Adverse Events	Every cycle while on treatment	Eligible and Treated Patients	participants	NUMBER
SECONDARY	Progression-free Survival	From start of treatment to time of progression or death, assessed up to 5 years	Eligible and Treated Patients	months	MEDIAN
SECONDARY	Overall Survival	Time from start of treatment to time of death or the date of last contact, assessed up to 5 years	Eligible and treated patients	months	MEDIAN

Source ClinicalTrials.gov

Results by group27

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Objective Tumor Response (Complete or Partial)	Pazopanib		0	90% Confidence Interval 0 to 14.6	percentage of participants
Percentage of Participants With Progression-free Survival (PFS) at 6 Months	Pazopanib		15.8	90% Confidence Interval 4.4 to 35.9	percentage of participants
Number of Patients With Grade 3 or Higher Adverse Events	Pazopanib	Anemia	3		participants
Number of Patients With Grade 3 or Higher Adverse Events	Pazopanib	Hypertension	3		participants
Number of Patients With Grade 3 or Higher Adverse Events	Pazopanib	Abdominal pain	2		participants
Number of Patients With Grade 3 or Higher Adverse Events	Pazopanib	Hyperglycemia	2		participants
Number of Patients With Grade 3 or Higher Adverse Events	Pazopanib	Hypoglycemia	2		participants
Number of Patients With Grade 3 or Higher Adverse Events	Pazopanib	Alanine aminotransferase increased	1		participants
Number of Patients With Grade 3 or Higher Adverse Events	Pazopanib	Ascites	1		participants
Number of Patients With Grade 3 or Higher Adverse Events	Pazopanib	Aspartate aminotransferase increased	1		participants

1 to 10 of 27Source ClinicalTrials.gov

See all 27 results by group

Participant flow3

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Pazopanib	22
Overall Study	COMPLETED	Pazopanib	19
Overall Study	NOT COMPLETED	Pazopanib	3

Source ClinicalTrials.gov

Adverse events93

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Anemia	Blood and lymphatic system disorders	Pazopanib	9	19
other	Sinus Bradycardia	Cardiac disorders	Pazopanib	1	19
other	Sinus Tachycardia	Cardiac disorders	Pazopanib	1	19
other	Tinnitus	Ear and labyrinth disorders	Pazopanib	2	19
other	Hearing Impaired	Ear and labyrinth disorders	Pazopanib	2	19
other	Ear Pain	Ear and labyrinth disorders	Pazopanib	1	19
other	Blurred Vision	Eye disorders	Pazopanib	3	19
other	Dysphagia	Gastrointestinal disorders	Pazopanib	3	19
other	Dyspepsia	Gastrointestinal disorders	Pazopanib	1	19
other	Dry Mouth	Gastrointestinal disorders	Pazopanib	3	19

1 to 10 of 93Source ClinicalTrials.gov

See all 93 adverse events

Adverse event totals3

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Pazopanib
Total, other adverse events	Pazopanib	19	19
Total, serious adverse events	Pazopanib	6	19

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants2

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years	Source
U10CA180868	NRG Oncology Network Group Operations Center	WOLMARK, NORMAN; Le, Quynh-Thu Xuan; MANNEL, ROBERT S.	NRG ONCOLOGY FOUNDATION, INC.	NATIONAL CANCER INSTITUTE	2014 to 2026	NIH RePORTER
U10CA027469	Gynecologic Oncology Group	DISAIA, PHILIP J.	GYNECOLOGIC ONCOLOGY GROUP	NATIONAL CANCER INSTITUTE	1985 to 2013	NIH RePORTER

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT01247571

GET https://conductscience.org/api/trials/v1/NCT01247571/results?page=2

API reference For AI assistants